Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • Legal Confusion Threatens to Slow Data Science

    Aug 3, 2016, 09:33 AM by Michael Croft
    Nature News & Comment | Daniel Himmelstein built a free online network to meld data from 28 public sources on links between drugs, genes, and diseases. Then he spent months chasing legal permission to republish the online data sets.
    Full story
  • Curable CEO Dr. Lisa Boyette Honored as One of the 100 Most Inspiring People in the Life Sciences industry

    Aug 3, 2016, 09:32 AM by Michael Croft
    PITTSBURGH, PA - Aug 3, 2016 - Curable, a non-profit research accelerator that applies engineering approaches to medicine to develop solutions for rare diseases, today announced that its Chief Executive Officer Lisa Boyette, MD, PhD, has been named a 2016 PharmaVOICE 100 honoree
    Full story
  • Biogen Draws Takeover Interest from Rival Drugmakers

    Aug 2, 2016, 16:00 PM by Michael Croft
    WSJ | Biotechnology giant Biogen Inc. has drawn takeover interest from drug companies including Merck & Co. and Allergan PLC, raising the possibility of another huge deal in the health-care industry.
    Full story
  • Definiens Launches Clinical Development Offering to Provide Services from Discovery to Commercialization to Maximize the Success of Drug Programs

    Aug 2, 2016, 10:13 AM by Michael Croft
    MUNICH, GERMANY - Aug 2, 2016 - Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of its Clinical Development Offering, making the company the premier provider of comprehensive tissue-based services from discovery to commercialization
    Full story
  • Setting the Body’s ‘Serial Killers’ Loose on Cancer

    Aug 2, 2016, 09:02 AM by Michael Croft
    The New York Times | After a long, intense pursuit, researchers are close to bringing to market a daring new treatment: cell therapy that turbocharges the immune system to fight cancer.
    Full story
  • Q&A Glaxo Exec Says Bioelectronics Is Not Science Fiction

    Aug 1, 2016, 22:21 PM by Michael Croft
    STAT | Glaxo and Verily Life Sciences will invest $715 million in Galvani Bioelectronics and hope to win approval for their implantable devices in several years.
    Full story
  • Data Management, New NGS Panels: News and Briefs

    Aug 1, 2016, 15:40 PM by Michael Croft
    Bio-IT World Briefs | News and product launches from bio IT, clinical IT, and diagnostics technologies include data management installation at Scripps Research Institute and new NGS panels for detection of extremely rare (low-frequency) mutations.
    Full story
  • IBMs cloud CTO Were in this game to win

    Jul 29, 2016, 12:07 PM by Michael Croft
    Computerworld | An industry focus is one of the key factors IBM is betting will set it apart from cloud competitors including Google, Microsoft and Amazon Web Services, IBM's top cloud exec says.
    Full story
  • New karyogram display improves Sapientia for clinical diagnosis

    Jul 29, 2016, 05:54 AM by Michael Croft
    CAMBRIDGE, UK - Jul 29, 2016 - As the use of whole genome and exome analysis grows it is increasing the workload for the Genomic Medicine Centres
    Full story
  • An Extraordinary Standard: New NIST Protein Could Spur Biopharmaceutical Innovation

    Jul 28, 2016, 15:46 PM by Michael Croft
    GAITHERSBURG, MD - Jul 28, 2016 - The National Institute of Standards and Technology (NIST) has issued one of the world’s most intricate measurement standards: an exhaustively analyzed antibody protein that the biopharmaceutical industry will use to help ensure the quality of treatments across a widening range of health conditions, including cancers, autoimmune disorders and infectious diseases
    Full story
  • How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company

    Jul 28, 2016, 15:03 PM by Michael Croft
    Forbes | BioMarin became one of the world's most valuable biotechs by jettisoning costly distractions and focusing on one thing: treating some of the rarest diseases on the planet.
    Full story
  • Taking Genomic Data Global

    Jul 28, 2016, 12:25 PM by Michael Croft
    MIT Technology Review | Startups focused on Asia are among those aiming to bring precision medicine to far more people.
    Full story
  • Microsoft’s Iowa data center cluster to reach 3.2M square feet

    Jul 28, 2016, 10:32 AM by Michael Croft
    Computerworld | Microsoft is creating some 3.2 million square feet of data center space in the West Des Moines, Iowa, area but in three separate locations. The combined investment is about $3.5 billion.
    Full story
  • Creative Biostructure Provides Three Biophysical Characterization Methods

    Jul 27, 2016, 23:32 PM by Michael Croft
    SHIRLEY, NY - Jul 28, 2016 - Creative Biostructure is a provider of membrane protein products and services. At here, we provide a variety of technologies to meet the requirements of each customer
    Full story
  • Eli Lilly CEO Lechleiter to Retire After Eight-Year Stint

    Jul 27, 2016, 10:11 AM by Michael Croft
    Xconomy | After eight years at the helm of Eli Lilly, a tenure characterized by a steadfast belief in home-grown research, rather than deals, John Lechleiter is retiring. David Ricks, who currently runs Lilly's diversified bio-medicines unit-which develops drugs for neurological and cardiovascular disorders, among other diseases-will be named CEO on Jan. 1
    Full story
  • Time to Remodel the Journal Impact Factor

    Jul 27, 2016, 10:10 AM by Michael Croft
    Nature News & Comment | Nature and the Nature journals are diversifying their presentation of performance indicators. Impact factor is crude and also misleading. It effectively undervalues papers in disciplines that are slow-burning or have lower characteristic citation rates. Accordingly, Nature has updated its online journal metrics page to include an array of additional bibliometric data.
    Full story
  • Bioelectronics Market to be Driven by Increasing Prevalence of Several Neural and Cardiac Diseases

    Jul 27, 2016, 05:40 AM by Michael Croft
    ALBANY, NY - Jul 27, 2016 - Bioelectronics is an emerging branch of medical science dealing with combined application of the principles of biology and electrical engineering
    Full story
  • Definiens Releases Tissue Studio® 4.3 and Developer XD 2.6 to Meet Quantification Demands in Translational Research

    Jul 26, 2016, 10:34 AM by Michael Croft
    MUNICH, GERMANY - Jul 26, 2016 - Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of the Tissue Studio 4
    Full story
  • Nvidias Quadro P6000 GPU blasts out 12 teraflops of performance

    Jul 26, 2016, 09:10 AM by Michael Croft
    Computerworld | Nvidia keeps upping the performance with each new GPU based on the Pascal architecture. Its latest, the Quadro P6000, can deliver 12 teraflops of single-precision performance, a teraflop more than the Titan X unveiled just last week.
    Full story
  • Pharma firms establish exclusive agreement

    Jul 26, 2016, 06:59 AM by Michael Croft
    SLOVAKIA, SLOVAKIA - Jul 26, 2016 - Slovakia-based contract development and manufacturing organisation (CDMO) Saneca Pharma has sold registration dossiers for more than 20 pharmaceutical products to Switzerland-headquartered Xantis Pharma as part of an exclusive agreement
    Full story
  • «
  • 331
  • 332
  • 333
  • 334
  • 335
  • 336
  • 337
  • 338
  • 339
  • 340 (current)
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy